Palatin Technologies (PTN) Receivables - Net (2011 - 2025)

Palatin Technologies' (PTN) quarterly Receivables - Net came in at $2.0 million in Q4 2025, down 70.96% on a QoQ basis from $6.9 million in Q3 2025.

Palatin Technologies (PTN) Receivables - Net (2011 - 2025) Analysis & Trends

Palatin Technologies (PTN) has 11 years of Receivables - Net data on file, last reported at $2.0 million in Q4 2025.

Quarterly Receivables - Net changed N/A year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (changed N/A YoY) and the FY2023 annual result came in at $2.9 million, up 63.8% from the prior year.
Receivables - Net slipped to $2.0 million in Q4 2025, from $6.9 million in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $6.9 million in Q3 2025 to a low of $583991.0 in Q4 2021.
A 4-year average of $2.0 million and a median of $1.8 million in 2022 frame the typical range for Receivables - Net.
Annual changes were most pronounced in 2021 — Receivables - Net sank 87.7% — and 2022, when it surged 209.42%.
Tracing PTN's Receivables - Net over 4 years: stood at $583991.0 in 2021, then surged by 209.42% to $1.8 million in 2022, then advanced by 29.84% to $2.3 million in 2023, then declined by 14.75% to $2.0 million in 2025.
The last three Receivables - Net figures came in at $2.0 million (Q4 2025), $6.9 million (Q3 2025), and $2.3 million (Q4 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Palatin Technologies	40.86 Mn	40.86 Mn	-

Download Data